Rigor Reviewed

Rigor-Reviewed Manuscript

15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial.

Name: Αlpha¹ Rigor Record — 15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial.
Item: 15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial.
Rating: 59
Author: Αlpha¹

Bethlehem L, Bartu L, Marke G, Mar P, Feldman S, Eggers J, Ruprecht C, Britton GJ, Aggarwala V, Bongers G, Li Z, Yang N, Hohmann EL, Mogno I, Faith JJ, Grinspan A

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 6 high issues for “15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
ReportingStatistical analysis partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Study-design details incomplete (controls, blinding, power)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This phase 1b RCT comparing a defined 15-strain LBP (MTC01) with FMT from the same donor is methodologically sound in its premise, ethics, resource description, data/code availability, and reporting transparency. The main weaknesses are the open-label design, small feasibility-based sample size (18 total, not the planned 15/group), and some statistical reporting gaps (threshold p-values, unverified assumptions, post-hoc analyses).

Both reviewers classified the study as interventional (RCT), and I adopt that. The statistics verification covered only 2 tests (1 consistent, 0 inconsistent) due to limited reporting of test statistics/df; most model-based estimates remain unverified. The citation check found no retracted or unresolved references. The integrity check flagged two low-severity internal contradictions (arm order, AE relatedness) that do not change the overall assessment.

8 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

The introduction cites prior FMT and LBP trials, acknowledges limitations of undefined fecal products, and justifies the need for defined LBPs. The hypothesis that strains with high engraftment frequencies will improve LBP efficacy is logically derived from prior observations. The paper also addresses limitations of prior research by directly comparing the same strains in FMT and LBP forms.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise, citing prior work on FMT and LBPs, and provides a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1]

“The recent approvals of two stool-derived therapeutics, live-jslm (Rebyota) and live-brpk (Vowst) ... mark a key milestone in the development of live microbial therapeutics. However, the undefined composition of these products also highlights our limited understanding of what is necessary and sufficient for success.”

paraphrase[Results, Manufacturing of LBP MTC01]

“Given prior observations that higher engraftment of FMT and LBP donor strains is predictive of relapse prevention in rCDI trials of microbial therapeutics, we hypothesized that an LBP comprised of strains with high FMT engraftment frequencies would facilitate high LBP engraftment and protection from relapse.”

direct quote[Introduction, paragraph 3]

“These shared donor-derived FMT and donor-isolated LBP drug products allowed us to compare the safety, efficacy, and engraftment of the same strains manufactured in vitro with the full spectrum donor sourced FMT fecal slurry at two matched doses.”